$UTHR

UNITED THERAPEUTICS Corp

United Therapeutics develops and markets therapies for people with serious diseases with unmet medical needs, and researches technologies to expand the availability of transplantable organs. Its commercial portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin, Remunity and RemunityPRO Pumps, Orenitram, and Adcirca for pulmonary arterial hypertension; Tyvaso DPI and Nebulized Tyvaso also treat pulmonary hypertension associated with interstitial lung disease. Unituxin treats high-risk neuroblastoma. The company sells these products through specialty pharmaceutical distributors in the United States and pharmaceutical distributors internationally, and sells Nebulized Tyvaso, Remodulin, and Unituxin outside the United States. United Therapeutics also has products in development for pulmonary and other diseases, and researches organ technologies including xenotransplantation, regenerative medicine, and ex vivo lung perfusion. Its principal executive offices are in Silver Spring, Maryland, and Durham, North Carolina.

1
3
1
—
$125.0M
ROTHBLATT MARTINE A
100%
See all $UTHR insider activity →

MAHON PAUL A sold $4.7M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $565.09 ($554.73–$577.19, $4.69M total) across 20 trades on 2026-11-19 under a Rule 10b5-1 trading plan.

ROTHBLATT MARTINE A sold $3.1M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 5,410 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $578.83 ($570.82–$586.74, $3.13M total) across 15 trades on 2026-11-18 under a Rule 10b5-1 trading plan.

UTHR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning UTHR (UNITED THERAPEUTICS Corp). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.

Recent UTHR coverage spans insider activity and financial news.

In the last 30 days, UTHR insiders filed 327 SEC Form 4 transactions — no purchases and 327 sales ($125.0M). The most active reporter was ROTHBLATT MARTINE A, Chairperson & CEO, with 297 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving UTHR

  • First-in-human xenotransplant trial start may generate modest positive sentiment.

    tradingview.com · Nov 20, 2026

  • Insider sale may signal modest negative sentiment.

    SEC EDGAR · Nov 19, 2026

  • Insider selling under a pre-arranged 10b5-1 plan is typically viewed as neutral to mildly negative, but it can still affect near-term sentiment.

    SEC EDGAR · Nov 19, 2026

  • This is an insider sale, not an operational or guidance catalyst, but it can still affect near-term sentiment and positioning.

    SEC EDGAR · Nov 18, 2026

  • Insider selling under a pre-arranged 10b5-1 plan is typically not a fundamental change, but it can still affect near-term sentiment and positioning.

    SEC EDGAR · Nov 17, 2026

AlphAI scores every news story that mentions UTHR with an AI model for sentiment and relevance, and aggregates insider trades from UNITED THERAPEUTICS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $UTHR

Score

Related tickers